Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 6Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Multiple Myeloma 61Lymphoma, Follicular 16Recurrence 13Lymphoma, Non-Hodgkin 12Lymphoma, Mantle-Cell 12Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, B-Cell, Marginal Zone 9Lymphoma, Large B-Cell, Diffuse 8Leukemia, Lymphocytic, Chronic, B-Cell 8Waldenstrom Macroglobulinemia 7Neoplasms 7Neoplasms, Plasma Cell 6Lymphoma, Large-Cell, Anaplastic 5Leukemia, Myeloid, Acute 5Immunoblastic Lymphadenopathy 5Lymphoma, T-Cell, Cutaneous 4Hodgkin Disease 4Carcinoma, Non-Small-Cell Lung 4Sezary Syndrome 3Prostatic Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, B-Cell 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Erythroblastic, Acute 3Leukemia 3

Interventions

pembrolizumab 51Ipilimumab 50Cyclophosphamide 43Nivolumab 41aldesleukin 30Interleukin-2 23Vemurafenib 20fludarabine 19Temozolomide 18fludarabine phosphate 15dabrafenib 15trametinib 12spartalizumab 10Radiotherapy 10Radiosurgery 10Dacarbazine 10CTLA-4 Antigen 10cobimetinib 9binimetinib 9poly ICLC 7encorafenib 7Paclitaxel 7atezolizumab 6Introns 6Biopsy 6montanide ISA 51 5Carboplatin 5epacadostat 4MART-1 Antigen 4Interferon alpha-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Melanoma × Bortezomib × Clear all
NCT00512798 2012-10-02

Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma

Vanderbilt-Ingram Cancer Center

Phase 1/2 Terminated
47 enrolled 9 charts
CNSDermatologic

Brain Neoplasms, Melanoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡